Agios Pharmaceuticals’ (AGIO) Outperform Rating Reaffirmed at Royal Bank of Canada

Royal Bank of Canada reissued their outperform rating on shares of Agios Pharmaceuticals (NASDAQ:AGIO) in a research report released on Friday morning, Benzinga reports. Royal Bank of Canada currently has a $55.00 price target on the biopharmaceutical company’s stock.

Other equities analysts have also recently issued reports about the stock. Leerink Partners cut shares of Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and lowered their price objective for the stock from $60.00 to $56.00 in a research report on Friday, September 27th. Cantor Fitzgerald reissued an “overweight” rating on shares of Agios Pharmaceuticals in a research note on Friday, September 20th. Scotiabank lifted their target price on shares of Agios Pharmaceuticals from $51.00 to $53.00 and gave the company a “sector outperform” rating in a research note on Friday. StockNews.com upgraded Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, October 16th. Finally, Raymond James restated an “outperform” rating and set a $51.00 target price on shares of Agios Pharmaceuticals in a report on Thursday, October 10th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, Agios Pharmaceuticals has an average rating of “Hold” and a consensus target price of $52.33.

Agios Pharmaceuticals Stock Performance

Shares of NASDAQ:AGIO opened at $44.87 on Friday. The stock has a market capitalization of $2.55 billion, a price-to-earnings ratio of 3.95, a PEG ratio of 0.45 and a beta of 0.75. Agios Pharmaceuticals has a 1-year low of $20.40 and a 1-year high of $53.28. The company has a 50 day moving average price of $44.62 and a 200 day moving average price of $42.23.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($1.69) earnings per share for the quarter, missing the consensus estimate of ($1.60) by ($0.09). The company had revenue of $8.60 million for the quarter, compared to the consensus estimate of $9.34 million. Agios Pharmaceuticals had a negative return on equity of 3.81% and a net margin of 2,051.38%. The business’s revenue was up 28.4% compared to the same quarter last year. During the same period in the prior year, the business earned ($1.51) earnings per share. On average, sell-side analysts expect that Agios Pharmaceuticals will post 7.54 EPS for the current fiscal year.

Insider Transactions at Agios Pharmaceuticals

In other news, CFO Cecilia Jones sold 2,542 shares of the business’s stock in a transaction that occurred on Thursday, September 26th. The stock was sold at an average price of $49.03, for a total transaction of $124,634.26. Following the sale, the chief financial officer now directly owns 20,158 shares in the company, valued at approximately $988,346.74. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other Agios Pharmaceuticals news, CEO Brian Goff sold 11,091 shares of Agios Pharmaceuticals stock in a transaction on Thursday, August 8th. The stock was sold at an average price of $42.75, for a total transaction of $474,140.25. Following the completion of the transaction, the chief executive officer now directly owns 78,792 shares of the company’s stock, valued at approximately $3,368,358. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Cecilia Jones sold 2,542 shares of the business’s stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $49.03, for a total transaction of $124,634.26. Following the completion of the sale, the chief financial officer now owns 20,158 shares in the company, valued at $988,346.74. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders own 4.93% of the company’s stock.

Hedge Funds Weigh In On Agios Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in AGIO. Acadian Asset Management LLC acquired a new stake in shares of Agios Pharmaceuticals during the second quarter worth approximately $37,000. Quest Partners LLC bought a new position in Agios Pharmaceuticals in the 2nd quarter valued at $40,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in Agios Pharmaceuticals by 21.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,058 shares of the biopharmaceutical company’s stock worth $94,000 after purchasing an additional 363 shares in the last quarter. CWM LLC grew its holdings in shares of Agios Pharmaceuticals by 554.7% during the third quarter. CWM LLC now owns 2,167 shares of the biopharmaceutical company’s stock worth $96,000 after purchasing an additional 1,836 shares during the last quarter. Finally, North Star Asset Management Inc. acquired a new stake in shares of Agios Pharmaceuticals in the second quarter valued at $216,000.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.